科学家开发BacID,这是针对致命癌症的无毒细菌疗法,预定进行2027年试验。 Scientists develop BacID, a non-toxic bacterial therapy targeting deadly cancers, set for 2027 trials.

来自马萨诸塞州阿姆赫斯特大学和欧内斯特制药公司的科学家开发了BacID,这是一种无毒细菌疗法,将癌症药物直接送入肿瘤,针对肝脏、卵巢和转移性乳腺癌等高死亡率癌症。 Scientists from the University of Massachusetts Amherst and Ernest Pharmaceuticals have developed BacID, a non-toxic bacterial therapy to deliver cancer drugs directly into tumors, targeting high-mortality cancers like liver, ovarian, and metastatic breast cancer. 该疗法使用基因工程的沙门氏菌株,这些菌株在阿司匹林触发时释放出药物,减少对健康组织造成的伤害。 The therapy uses genetically engineered Salmonella strains that release drugs when triggered by aspirin, reducing harm to healthy tissue. BacID将于2027年开始临床试验。 Over a decade in the making, BacID is set to begin clinical trials in 2027.